Statin treatment in primary and secondary prevention-A statement;Traitement des dyslipidémies par les statines en prévention primaire et secondaire

Revue Medicale Suisse

Volumn 10, Issue 455, 2014, Pages 2430-2433

  Mach, François ^a   Riesen, Walter F ^b   Rodondi, Nicolas ^c   Von Eckardstein, Arnold ^d  

^a Service de Cardiologie   (Switzerland)

^b Université de Berne ^*  (Switzerland)

^c UNIVERSITY OF BERN   (Switzerland)

^d UNIVERSITY HOSPITAL ZURICH   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LOW DENSITY LIPOPROTEIN CHOLESTEROL;

ARTICLE; ASYMPTOMATIC DISEASE; CARDIOVASCULAR RISK; HUMAN; ISCHEMIC HEART DISEASE; PRIMARY PREVENTION; RISK REDUCTION; SECONDARY PREVENTION; CARDIOVASCULAR DISEASES; RISK FACTOR;

CARDIOVASCULAR DISEASES; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; PRIMARY PREVENTION; RISK FACTORS; SECONDARY PREVENTION;

EID: 84919391370     PISSN: 16609379     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (17)

1. Yusuf S, et al. Effect of potentially modifiable risk factors associated with myocardial infarction in 52 countries (the INTERHEART study) : Case-control study. Lancet 2004;364:937-52.
2. Law MR, Wald NJ, Thompson SG. By how much and how quickly does reduction in serum cholesterol concentration lower risk of ischaemic heart disease BMJ 1994;308:367-72.
3. Law MR. Lowering heart disease risk with cholesterolreduction : Evidence from observational studies and clinical trials. Eur Heart J Suppl 1999;(Suppl. S):S3-8.
4. CTT Collaboration. Efficacy and safety of more intensive lowering of LDL cholesterol : A meta-analysis of data from 170 000 participants in 26 randomised trials. Lancet 2010;376:1670-81.
5. Brugts JJ, et al. The benefits of statins in people without established cardiovascular disease but with cardiovascular risk factors : A meta-analysis of randomized controlled trials. BMJ 2009;338:b2376.
6. Mills EJ, et al. Primary prevention of cardiovascular mortality and events with statin treatments : A network meta-analysis involving more than 65 000 patients. JACC 2008;52:1769-81.
7. Tonelli M, et al. Efficacy of statins for primary prevention in people at low cardiovascular risk : A metaanalysis. CMAJ 2011;183:E1189-202.
8. Simpson RJ, Mendys P. The effects of adherence and persistence on clinical outcomes in patients treated with statins : A systematic review. J Clin Lipidol 2010; 4:462-71.
9. Gomez-Sandoval YH, et al. Statin discontinuation in high-risk patients : A systematic review of the evidence. Curr Pharm Des 2011;17:3669-89.
10. Shalev V, et al. Continuation of statin treatment and all-cause mortality : A population-based cohort study. Arch Intern Med 2009;169:260-8.
11. Perreault S, et al. Effect of statin adherence on cerebrovascular disease in primary prevention. Am J Med 2009;122:647-55.
12. Risselada R, et al. Withdrawal of statins and risk of subarachnoid hemorrhage. Stroke 2009;40:2887-92.
13. Colivicchi F, et al. Discontinuation of statin therapy and clinical outcome after ischemic stroke. Stroke 2007;38:2652-7.
14. Sattar N, et al. Statins and risk of incident diabetes : A collaborative meta-analysis of randomized statin trials. Lancet 2010;375:735-42.
15. Preiss D, et al. Risk of incident diabetes with intensive-dose compared with moderate-dose statin therapy : A meta-analysis. JAMA 2011;305:2556-64.
16. Fernandez G, et al. Statin myopathy : A common dilemma not reflected in clinical trials. Cleve Clin J Med 2011;78:393-403.
17. van Vark LC, et al. Angiotensin-converting enzyme inhibitors reduce mortality in hypertension : A metaanalysis of randomized clinical trials of renin-angiotensin-aldosterone system inhibitors involving 158 998 patients. Eur Heart J 2012;33:2088-97.